info@marketresearchfuture.com 📞 +1 628 258 0071(US)  📞 +44 2035 002 764(UK)
Upper Gastrointestinal (GI) Series Market Research Report - Forecast to 2027

upper GI series market research report, by test types (the standard barium upper GI series & double-contrast upper GI series), by type of imaging material (barium swallow, barium meal, barium follow-through), by application (esophageal reflux, esophageal varices, ulcers, hiatal hernias & others), by end users (hospitals, clinics & laboratories and other) -Forecast till 2027

ID: MRFR/Pharma/0330-HCR | February 2021 | Region: Global | 146 pages

Upper GI Series Market Speak to Analyst Request a Free Sample

Upper GI Series Market Overview


Globally, the upper GI series market is expected to grow at a huge rate attaining a CAGR value of about 4.5% during the forecast period. From the market scenario, it has been noted that the upper GI series also called contrast radiography helped in detecting the abnormalities in the gastrointestinal passage. From the upper gastrointestinal study, it has been found that contrast media is either inserted or is ingested into the digestive passage. In fact for detection of the abnormalities, an X-ray of the respective portion was being conducted. In the year 2010, it was found that the National Institute of Digestive and Diabetes kidney diseases has been found that 70-80 million people were being affected by GI tract-related disorders.


A certain rise in GI-related disorders takes place due to poor diet and the rise in the geriatric population. In fact from the market scenario, it was found that it gave information about the market structure in the upcoming years. It even gave detailed information about the segments and subsegments playing a great role in the development of the market. The upper gastrointestinal test is a series of X-rays being conducted for detecting the disorders associated with the esophagus, stomach, and small intestine if in case a patient has swallowed barium sulfate solution. Swallowing up of barium solution is an excellent procedure used for detecting pain, problems related to swallowing, and many more.


COVID 19 Analysis


The outburst of COVID has affected the world at a wide rate. It hindered the opportunities of the market and turned the technology upside down. Many companies started resuming their work after the recovery from COVID. This pandemic led to the disruption of the value chain along with a hindrance in the financial status of the company. It disrupted the consumer's market value thus decreasing the market size. The production unit and the manufacturing status were highly disrupted. The labor status of the company has deteriorated whereas their financial status was being destroyed. The government started donating funds for the welfare of the people.


Upper GI Series Market Dynamics


Drivers


The rise in upper GI series market size is due to the rise in people suffering from poor diet conditions along with rising in the geriatric population rate. The rise in prevalence of gastro diseases rate along with upper GI cancer has changed the lifestyle of the people. This has helped in boosting up the upper GI series market growth. Adoption of new technologies along with using cost-effective methods has helped in driving up the market growth rate. The rise in the aging population with the support of the government has helped in improving the research activities thus helping in pushing up the market size. Availability of new therapeutic methods along with limited usage of those methods has deteriorated the market size thus restraining the market growth.


Opportunities


Clinical activities so conducted helps in raising the trials of GI diagnosis and raises the opportunities if the upper GI series market value. Large capita for healthcare infrastructure has raised the opportunities of the market and has helped in the expansion of upper GI series market growth. The presence of a large lucrative patient pool helps in rising the market size. The improvement of size takes place due to using revised codes that are to be used by different GI series of different healthcare organizations. Usage of different and trained professionals which helps in rising market size.


Challenges


High expenses of the treatments will reduce the market size.


Restraints


The presence of large therapeutic areas and many of the gastro-related abnormalities offer fewer treatment options which is the major restraining factor of upper GI series market growth. Setup of more pharma companies which helps in recognition of more innovative treatments and vast technologies which helps in the development and raises the opportunities of market size. The rapid change in eating habits of the population along with the rise of hepatitis C at an alarming rate boosts up the need for radiography thus spurring up the market size.


Upper GI Series Market Segmentation


The market segmentation it has been found that the market is being segmented into test type, GI upper series made up of upper barium material along with double-contrast upper GI series. As per the imaging material, it has been found that the market has been divided into barium swallow, a meal made up of barium and barium follow-through.


As per the application, it has been found that on market segmentation it has been found that the market is being divided into esophageal reflux, hiatal hernias, and ulcers.


As per the end-users, it has been bifurcated into medical centers, clinics, and many more.


Growth in technology led to the adoption of various x-ray techniques along with adopting gastrointestinal bleeding treatment methods. It in fact led to the discovery of endoscopic and endoscopic mechanical devices which helps in managing the arterial bleeding from the GI tract. It was also found that these bleeding treatments are used for visualizing the upper GI tract along with the lower GI tract. The ultrasound system so discovered has helped in the treatment of digestive cancer diseases with minimum invasive care.


Figure 1- Upper Gastrointestinal (GI) Series Market, by region

 upper GI series market


Sources- Annual reports, Press release, White paper, Company Presentation


Upper GI Series Market Regional Analysis


The presence of a large number of patients along with the setting up of the well-developed medical units, and the rise in the aging population improves the growth of the gastro market. Besides all this, it was reported that the United States reports hold the largest upper GI series market value. Besides it, it has been found that the European region has occupied the second-largest upper GI series market share after the Aasia African region. Moreover, it has been found that the Asia African market is marked to be the fastest-growing market due to the presence of more developing areas and medical centers. This region has been marked to be the largest market where it has adopted a number of cost-effective and efficient techniques. Besides, the Middle East and the African region have been marked to hold less market upper GI series market share.


Upper GI Series Market Competitive Landscape


Some of the manufacturing industries playing a huge role in the market growth include Gastrointestinal Specialists LLC of the United Kingdom, Ironwood Pharmaceuticals Inc. The United States, Eisai Co. Ltd of Japan, AstraZeneca of the United Kingdom, Cadila Pharmaceutical Ltd of the Indian region, Novodac Technologies Inc. of the Canadian region, Purdue Pharma LP of the United States, Alfa Wassermann SPA of Germany, and many more. Their various strategies include collaboration, acquisition, expansion and adopting different company portfolios helps in raising up the market strength.


Recent Developments


EISAI Co. Ltd on its collaboration with AJINOMOTO Co. inc led to the formation of various gastrointestinal techniques. They also launched certain gastro products which increased the upper GI series market value. GE healthcare a renounceable United States company launched an effective visualization effective methods for


Report Overview


From upper GI series market analysis it was found that the report provides detailed information about the drivers and the challenging factors emerging in the market. In fact, the report symbolized the growth map during the upper GI series market forecast period. From the report analysis, it was found that from the market analysis you can draw graphs and help in analyzing the market growth. It gave information about the price analysis, porter five analysis, value chain analysis and many more. It even gives details about the new upper GI series market trends and opportunities playing a great role in the market.it gives information about the historical path and the market revenue projecting up in the marketing environment. It gives information about the competitive players and their strategic plans so operated by them. It even gave detailed information about the COVID impact and its recovery situations on the key players.



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   4.5% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   test types, type of imaging material, application and end users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   GastroIntestinal Specialists LLC. (UK), Eisai Co., Ltd (Japan), Cadila Pharmaceuticals Limited (India), Purdue Pharma L.P. (US), Alfa Wassermann SPA (Germany), Novadaq Technologies Inc. (Canada), AstraZeneca (UK), Ironwood Pharmaceuticals Inc. (US)
  Key Market Opportunities   increasing aging population and government support for research
  Key Market Drivers   increasing prevalence of GI diseases & gastric cancer, and changing lifestyle.


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

High incidence of GI diseases and changing lifestyles of patients are major drivers of the global upper gastrointestinal (GI) series market.

Development of diagnostic techniques and government support for research on GI diseases are prime opportunities for growth in the global gastrointestinal (GI) series market.

Alternative therapies and limited applications of current diagnostic methods can hamper the global upper gastrointestinal (GI) series market growth.

The Americas can dominate the global upper gastrointestinal (GI) series market till 2027.

Eisai Co., Ltd, Purdue Pharma L.P., AstraZeneca, Cadila Pharmaceuticals Limited, GastroIntestinal Specialists LLC, Alfa Wassermann SPA, Novadaq Technologies Inc., and Ironwood Pharmaceuticals Inc. are major players of the global upper gastrointestinal (GI) series market.